OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.06 Million TWD | -105.7% |
| 2022 | 211.62 Million TWD | 329.15% |
| 2021 | 49.31 Million TWD | -71.01% |
| 2020 | 170.09 Million TWD | 15.34% |
| 2019 | 147.47 Million TWD | 4.06% |
| 2018 | 141.72 Million TWD | 8.53% |
| 2017 | 130.57 Million TWD | 20.9% |
| 2016 | 108 Million TWD | -4.63% |
| 2015 | 113.24 Million TWD | 194.49% |
| 2014 | 38.45 Million TWD | -72.74% |
| 2013 | 141.09 Million TWD | 28.01% |
| 2012 | 110.22 Million TWD | 46.78% |
| 2011 | 75.09 Million TWD | 56.66% |
| 2010 | 47.93 Million TWD | -23.7% |
| 2009 | 62.81 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 12.78 Million TWD | 184.19% |
| 2024 Q2 | 31.34 Million TWD | 145.17% |
| 2023 Q4 | -15.18 Million TWD | -178.24% |
| 2023 FY | -12.06 Million TWD | -105.7% |
| 2023 Q1 | 14.91 Million TWD | 3819.2% |
| 2023 Q3 | 19.4 Million TWD | -48.66% |
| 2023 Q2 | 37.8 Million TWD | 153.45% |
| 2022 Q3 | 72.18 Million TWD | -9.95% |
| 2022 Q1 | 59.69 Million TWD | 1420.79% |
| 2022 FY | 211.62 Million TWD | 329.15% |
| 2022 Q4 | -401 Thousand TWD | -100.56% |
| 2022 Q2 | 80.15 Million TWD | 34.28% |
| 2021 Q1 | 7.5 Million TWD | -85.82% |
| 2021 FY | 49.31 Million TWD | -71.01% |
| 2021 Q4 | 3.92 Million TWD | -22.35% |
| 2021 Q3 | 5.05 Million TWD | 1965.31% |
| 2021 Q2 | -271 Thousand TWD | -103.61% |
| 2020 Q4 | 52.88 Million TWD | 105.68% |
| 2020 Q2 | 8.31 Million TWD | -83.21% |
| 2020 FY | 170.09 Million TWD | 15.34% |
| 2020 Q1 | 49.51 Million TWD | 54.67% |
| 2020 Q3 | 25.71 Million TWD | 209.26% |
| 2019 Q1 | 19.75 Million TWD | -56.2% |
| 2019 Q3 | 30.12 Million TWD | 11.21% |
| 2019 Q2 | 27.08 Million TWD | 37.11% |
| 2019 Q4 | 32.01 Million TWD | 6.27% |
| 2019 FY | 147.47 Million TWD | 4.06% |
| 2018 Q2 | 18.57 Million TWD | -53.5% |
| 2018 Q3 | 38.09 Million TWD | 105.05% |
| 2018 Q4 | 45.1 Million TWD | 18.42% |
| 2018 FY | 141.72 Million TWD | 8.53% |
| 2018 Q1 | 39.94 Million TWD | 96.18% |
| 2017 Q3 | 40.98 Million TWD | 15.4% |
| 2017 Q4 | 20.36 Million TWD | -50.32% |
| 2017 FY | 130.57 Million TWD | 20.9% |
| 2017 Q1 | 33.71 Million TWD | 1148.09% |
| 2017 Q2 | 35.51 Million TWD | 5.36% |
| 2016 FY | 108 Million TWD | -4.63% |
| 2016 Q3 | 16.59 Million TWD | -57.5% |
| 2016 Q4 | 2.7 Million TWD | -83.72% |
| 2016 Q2 | 39.04 Million TWD | -21.38% |
| 2016 Q1 | 49.66 Million TWD | 84.91% |
| 2015 FY | 113.24 Million TWD | 194.49% |
| 2015 Q4 | 26.85 Million TWD | 0.0% |
| 2015 Q3 | 26.85 Million TWD | -9.77% |
| 2015 Q2 | 29.76 Million TWD | 0.0% |
| 2015 Q1 | 29.76 Million TWD | 644.89% |
| 2014 Q1 | 15.23 Million TWD | -49.38% |
| 2014 Q2 | 15.23 Million TWD | 0.0% |
| 2014 Q4 | 3.99 Million TWD | 0.0% |
| 2014 Q3 | 3.99 Million TWD | -73.77% |
| 2014 FY | 38.45 Million TWD | -72.74% |
| 2013 Q2 | 40.45 Million TWD | 0.0% |
| 2013 Q1 | 40.45 Million TWD | 40.93% |
| 2013 Q3 | 30.09 Million TWD | -25.61% |
| 2013 Q4 | 30.09 Million TWD | 0.0% |
| 2013 FY | 141.09 Million TWD | 28.01% |
| 2012 FY | 110.22 Million TWD | 46.78% |
| 2012 Q3 | 28.7 Million TWD | 0.0% |
| 2012 Q4 | 28.7 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 FY | 75.09 Million TWD | 56.66% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2010 FY | 47.93 Million TWD | -23.7% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 62.81 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 702.88 Million TWD | 101.716% |
| Apex Medical Corp. | 194.21 Million TWD | 106.211% |
| Applied BioCode Corporation | -186.7 Million TWD | 93.539% |